Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of equities analysts have weighed in on RANI shares. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Rani Therapeutics in a research note on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a research report on Monday, December 29th.

Hedge Funds Weigh In On Rani Therapeutics

Several institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new stake in Rani Therapeutics during the fourth quarter worth $11,475,000. AWM Investment Company Inc. purchased a new position in Rani Therapeutics in the fourth quarter valued at $8,775,000. SymBiosis Capital Partners LLC acquired a new position in shares of Rani Therapeutics in the fourth quarter worth about $8,505,000. Armistice Capital LLC purchased a new stake in shares of Rani Therapeutics during the 2nd quarter worth about $1,619,000. Finally, Siren L.L.C. acquired a new stake in shares of Rani Therapeutics during the 4th quarter valued at about $2,700,000. 30.19% of the stock is owned by hedge funds and other institutional investors.

Rani Therapeutics Price Performance

NASDAQ RANI opened at $1.29 on Friday. Rani Therapeutics has a 1 year low of $0.39 and a 1 year high of $3.87. The company has a market capitalization of $156.75 million, a PE ratio of -1.63 and a beta of 0.41. The company has a fifty day moving average of $1.35 and a 200 day moving average of $1.18.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.